Kevin DeGeeter
Stock Analyst at Oppenheimer
(0.04)
# 3,986
Out of 4,667 analysts
44
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.27 | +1,632.28% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $8.71 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $3.55 | +577.01% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $16.74 | +485.42% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $17.22 | +625.94% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $1.61 | +1,021.50% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $6.07 | +213.01% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $1.19 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $4.38 | +13,600.82% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $150 → $158 | $386.56 | -59.04% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $52.45 | +195.52% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.50 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.99 | +401.00% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $255 | $0.39 | +65,825.54% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $180 | $1.39 | +12,849.64% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $56.57 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.98 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $12.94 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.63 | +2,976.92% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.21 | +7,070.17% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.02 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $150 | $0.39 | +38,351.68% | 1 | Aug 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $15.68 | +1,334.95% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $14.84 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.35 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.27
Upside: +1,632.28%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $8.71
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $3.55
Upside: +577.01%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $16.74
Upside: +485.42%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $17.22
Upside: +625.94%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $1.61
Upside: +1,021.50%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $6.07
Upside: +213.01%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $1.19
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $4.38
Upside: +13,600.82%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $150 → $158
Current: $386.56
Upside: -59.04%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $52.45
Upside: +195.52%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.50
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $4.99
Upside: +401.00%
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $0.39
Upside: +65,825.54%
Mar 2, 2021
Initiates: Outperform
Price Target: $180
Current: $1.39
Upside: +12,849.64%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $56.57
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.98
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $12.94
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $1.63
Upside: +2,976.92%
Apr 8, 2020
Initiates: Outperform
Price Target: $15
Current: $0.21
Upside: +7,070.17%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.02
Upside: -
Aug 3, 2017
Initiates: Buy
Price Target: $150
Current: $0.39
Upside: +38,351.68%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $15.68
Upside: +1,334.95%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $14.84
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $4.35
Upside: -